Zacks: Brokerages Anticipate SI-BONE, Inc. (NASDAQ:SIBN) to Announce -$0.43 EPS

Analysts expect that SI-BONE, Inc. (NASDAQ:SIBNGet Rating) will announce ($0.43) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have provided estimates for SI-BONE’s earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.48). SI-BONE posted earnings per share of ($0.37) in the same quarter last year, which would indicate a negative year over year growth rate of 16.2%. The company is scheduled to issue its next quarterly earnings report after the market closes on Monday, January 1st.

According to Zacks, analysts expect that SI-BONE will report full-year earnings of ($1.77) per share for the current year, with EPS estimates ranging from ($1.85) to ($1.64). For the next financial year, analysts expect that the business will post earnings of ($1.55) per share, with EPS estimates ranging from ($1.63) to ($1.42). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow SI-BONE.

SI-BONE (NASDAQ:SIBNGet Rating) last issued its quarterly earnings data on Monday, February 28th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06). The company had revenue of $25.23 million during the quarter. SI-BONE had a negative return on equity of 38.10% and a negative net margin of 62.75%. During the same period in the previous year, the business posted ($0.28) earnings per share.

SIBN has been the subject of a number of research analyst reports. Morgan Stanley decreased their price target on SI-BONE from $30.00 to $28.00 and set an “overweight” rating for the company in a research report on Tuesday, March 1st. Needham & Company LLC reaffirmed a “buy” rating and set a $32.00 price target on shares of SI-BONE in a research report on Monday, January 10th. Bank of America decreased their price target on SI-BONE from $43.00 to $36.00 and set a “buy” rating for the company in a research report on Tuesday, January 18th. Cantor Fitzgerald initiated coverage on SI-BONE in a research report on Thursday, April 7th. They set an “overweight” rating and a $34.00 price target for the company. Finally, Zacks Investment Research downgraded SI-BONE from a “hold” rating to a “sell” rating in a research report on Wednesday, April 13th. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to MarketBeat, SI-BONE currently has an average rating of “Buy” and a consensus target price of $33.44.

Shares of SI-BONE stock opened at $21.69 on Wednesday. The stock has a market capitalization of $726.40 million, a P/E ratio of -12.76 and a beta of 1.41. SI-BONE has a 52 week low of $17.96 and a 52 week high of $37.21. The business has a 50 day moving average of $20.84. The company has a current ratio of 10.41, a quick ratio of 9.73 and a debt-to-equity ratio of 0.26.

In other news, Director Jeffrey W. Dunn sold 4,454 shares of the firm’s stock in a transaction on Wednesday, February 16th. The stock was sold at an average price of $20.38, for a total value of $90,772.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Laura Francis sold 4,777 shares of the firm’s stock in a transaction on Wednesday, February 16th. The stock was sold at an average price of $20.38, for a total value of $97,355.26. The disclosure for this sale can be found here. Over the last three months, insiders have sold 14,546 shares of company stock valued at $296,447. 7.00% of the stock is owned by corporate insiders.

Several institutional investors have recently bought and sold shares of the company. Champlain Investment Partners LLC bought a new stake in SI-BONE during the fourth quarter valued at $43,762,000. Brown Advisory Inc. boosted its stake in SI-BONE by 36.4% during the fourth quarter. Brown Advisory Inc. now owns 3,090,786 shares of the company’s stock valued at $68,646,000 after buying an additional 825,476 shares during the period. American Century Companies Inc. boosted its stake in SI-BONE by 309.1% during the third quarter. American Century Companies Inc. now owns 1,007,009 shares of the company’s stock valued at $21,570,000 after buying an additional 760,836 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in SI-BONE during the fourth quarter valued at $16,445,000. Finally, BlackRock Inc. boosted its stake in SI-BONE by 12.7% during the fourth quarter. BlackRock Inc. now owns 2,699,798 shares of the company’s stock valued at $59,962,000 after buying an additional 304,050 shares during the period.

About SI-BONE (Get Rating)

SI-BONE, Inc, a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures.

Featured Stories

Get a free copy of the Zacks research report on SI-BONE (SIBN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SI-BONE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-BONE and related companies with MarketBeat.com's FREE daily email newsletter.